RATIONALE: Chronic nicotine administration decreases the functioning of the cystine-glutamate antiporter system x(c)- which is hypothesized to promote nicotine-taking and nicotine-seeking behaviors. N-acetylcysteine (NAC), a cystine pro-drug, increases the activity of the cystine-glutamate antiporter system x(c)-. Thus, NAC could potentially reverse nicotine-induced alterations in glutamatergic transmission and decrease nicotine taking and seeking. OBJECTIVES AND METHODS: To test this hypothesis in the present study, the effects of acute NAC treatment (30, 60, and 90 mg/kg, i.p.) on nicotine (fixed- and progressive-ratio schedules) and food (fixed-ratio schedule) self-administration were assessed in rats. In addition, the effects of acute NAC treatment on cue-induced reinstatement of nicotine- and food-seeking behaviors were investigated. Finally, the effects of repeated daily NAC administration (60 mg/kg, i.p., 14 days) on nicotine and food self-administration were assessed. RESULTS: Acute NAC administration decreased nicotine self-administration but not food responding under a fixed-ratio schedule of reinforcement. In addition, acute NAC administration showed a nonsignificant trend in attenuating nicotine self-administration under a progressive-ratio schedule that was similar to the dose-response function under the fixed-ratio schedule. Furthermore, repeated NAC administration decreased nicotine self-administration from day 6 to 14 compared with vehicle treatment, with no indication of tolerance development. By contrast, repeated NAC administration decreased food responding from day 6 to 8 compared with vehicle treatment and showed rapid development of tolerance. Finally, acute NAC administration attenuated cue-induced reinstatement of nicotine and food seeking. CONCLUSIONS: Altogether, these findings suggest that NAC may be useful in promoting smoking cessation in humans.
RATIONALE: Chronic nicotine administration decreases the functioning of the cystine-glutamate antiporter system x(c)- which is hypothesized to promote nicotine-taking and nicotine-seeking behaviors. N-acetylcysteine (NAC), a cystine pro-drug, increases the activity of the cystine-glutamate antiporter system x(c)-. Thus, NAC could potentially reverse nicotine-induced alterations in glutamatergic transmission and decrease nicotine taking and seeking. OBJECTIVES AND METHODS: To test this hypothesis in the present study, the effects of acute NAC treatment (30, 60, and 90 mg/kg, i.p.) on nicotine (fixed- and progressive-ratio schedules) and food (fixed-ratio schedule) self-administration were assessed in rats. In addition, the effects of acute NAC treatment on cue-induced reinstatement of nicotine- and food-seeking behaviors were investigated. Finally, the effects of repeated daily NAC administration (60 mg/kg, i.p., 14 days) on nicotine and food self-administration were assessed. RESULTS: Acute NAC administration decreased nicotine self-administration but not food responding under a fixed-ratio schedule of reinforcement. In addition, acute NAC administration showed a nonsignificant trend in attenuating nicotine self-administration under a progressive-ratio schedule that was similar to the dose-response function under the fixed-ratio schedule. Furthermore, repeated NAC administration decreased nicotine self-administration from day 6 to 14 compared with vehicle treatment, with no indication of tolerance development. By contrast, repeated NAC administration decreased food responding from day 6 to 8 compared with vehicle treatment and showed rapid development of tolerance. Finally, acute NAC administration attenuated cue-induced reinstatement of nicotine and food seeking. CONCLUSIONS: Altogether, these findings suggest that NAC may be useful in promoting smoking cessation in humans.
Authors: Khaled Moussawi; Wenhua Zhou; Haowei Shen; Carmela M Reichel; Ronald E See; David B Carr; Peter W Kalivas Journal: Proc Natl Acad Sci U S A Date: 2010-12-20 Impact factor: 11.205
Authors: Shelley L Amen; Linda B Piacentine; Muhammad E Ahmad; Shi-Jiang Li; John R Mantsch; Robert C Risinger; David A Baker Journal: Neuropsychopharmacology Date: 2010-12-15 Impact factor: 7.853
Authors: Lori A Knackstedt; Steven LaRowe; Pascale Mardikian; Robert Malcolm; Himanshu Upadhyaya; Sarra Hedden; Athina Markou; Peter W Kalivas Journal: Biol Psychiatry Date: 2008-12-21 Impact factor: 13.382
Authors: Paul J Kenny; Elena Chartoff; Marisa Roberto; William A Carlezon; Athina Markou Journal: Neuropsychopharmacology Date: 2008-04-16 Impact factor: 7.853
Authors: Erin A McClure; Nathaniel L Baker; Cassandra D Gipson; Matthew J Carpenter; Amanda P Roper; Brett E Froeliger; Peter W Kalivas; Kevin M Gray Journal: Am J Drug Alcohol Abuse Date: 2014-07-25 Impact factor: 3.829
Authors: Roeland F Struik; Nathan J Marchant; Roel de Haan; Huub Terra; Yvar van Mourik; Dustin Schetters; Madison R Carr; Marcel van der Roest; Tim S Heistek; Taco J De Vries Journal: Neuropsychopharmacology Date: 2019-06-26 Impact factor: 7.853
Authors: B M Siemsen; C M Reichel; K C Leong; C Garcia-Keller; C D Gipson; S Spencer; J A McFaddin; K N Hooker; P W Kalivas; M D Scofield Journal: Neuroscience Date: 2019-03-26 Impact factor: 3.590
Authors: Fawaz Alasmari; Laura E Crotty Alexander; Jessica A Nelson; Isaac T Schiefer; Ellen Breen; Christopher A Drummond; Youssef Sari Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-03-27 Impact factor: 5.067
Authors: Kathryn J Reissner; Cassandra D Gipson; Phuong K Tran; Lori A Knackstedt; Michael D Scofield; Peter W Kalivas Journal: Addict Biol Date: 2014-02-25 Impact factor: 4.280
Authors: Cassandra D Gipson; Kathryn J Reissner; Yonatan M Kupchik; Alexander C W Smith; Neringa Stankeviciute; Megan E Hensley-Simon; Peter W Kalivas Journal: Proc Natl Acad Sci U S A Date: 2013-05-13 Impact factor: 11.205